Stock Events

Stock Events

Central Asia Lumeichun Biotechnology 

$0.175000
0
+$0.00+0%Monday 20:00

Statistics

Day High
0.175
Day Low
0.175
52W High
3.5
52W Low
0.001
Volume
44
Avg. Volume
117
Mkt Cap
55.76M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

0.33%Profit Margin
Profitable
2015
2021
2022
2023
2024
2025
1.21MRevenue
4,000Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7B
Alkermes plc is involved in the development of pharmaceuticals that treat substance abuse, making it a direct competitor in the addiction treatment market.
Indonesia Energy
INDO
Mkt Cap41.08M
Indivior PLC specializes in treatments for opioid addiction, competing in the same space as TOCCA Life's focus on substance abuse recovery.
Opko Health
OPK
Mkt Cap1.16B
OPKO Health, Inc. has a diverse portfolio that includes treatments for addiction, positioning it as a competitor in the healthcare sector focused on recovery.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie Inc. manufactures drugs for various conditions, including substance abuse, making it a broader competitor in the pharmaceutical industry.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson offers a wide range of healthcare products, including treatments for addiction, competing on a global scale in the healthcare market.
Pfizer
PFE
Mkt Cap158.45B
Pfizer Inc. is a global pharmaceutical company with products that could compete in the addiction treatment space, offering alternative solutions.
Merck
MRK
Mkt Cap356.01B
Merck & Co., Inc. develops medicines for various health conditions, potentially including addiction, making it a competitor in the pharmaceutical industry.
Novartis
NVS
Mkt Cap268B
Novartis AG, a global healthcare company, has a broad portfolio that may include addiction treatment solutions, competing in the healthcare market.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, Inc. is known for its innovative treatments in various therapeutic areas, potentially competing with TOCCA Life in the addiction recovery sector.

About

Central Asia Lumeichun Biotechnology Inc. operates sober living residences in the United States. It offers life coaching programs through the provision of equipment, materials, and demonstrations, including cooking, cleaning, household maintenance, basic math and banking, computer and writing skills, life coaching, transitional living management, graphic art, information technology, marketing, television production, interest rate theories, credit cost valuation, mortgage banking, and business etiquette, models, infrastructures, and ethics, as well as entrepreneurship and sports events and fitness. The company was formerly known as TOCCA Life Holdings, Inc. and changed its name to Central Asia Lumeichun Biotechnology Inc. in October 2025. The company is based in Winter Park, Florida.
Show More
CEO
Mr. Stephen W. Carnes
Country
United States
ISIN
US8888472094

Listings

OTC Link
US
ZYLM

0 Comments

Share your thoughts

FAQs

What is Central Asia Lumeichun Biotechnology stock price today?▼
The current price of ZYLM is $0.18 USD — it has increased by +0% in the past 24 hours. Watch Central Asia Lumeichun Biotechnology stock price performance more closely on the chart.
What is Central Asia Lumeichun Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Central Asia Lumeichun Biotechnology stocks are traded under the ticker ZYLM.
Is Central Asia Lumeichun Biotechnology stock price growing?▼
ZYLM stock has fallen by -0% compared to the previous week, the month change is a +0% rise, over the last year Central Asia Lumeichun Biotechnology has showed a -95% decrease.
What is Central Asia Lumeichun Biotechnology market cap?▼
Today Central Asia Lumeichun Biotechnology has the market capitalization of 55.76M
What is Central Asia Lumeichun Biotechnology revenue for the last year?▼
Central Asia Lumeichun Biotechnology revenue for the last year amounts to 1.21M USD.
What is Central Asia Lumeichun Biotechnology net income for the last year?▼
ZYLM net income for the last year is 4,000 USD.
In which sector is Central Asia Lumeichun Biotechnology located?▼
Central Asia Lumeichun Biotechnology operates in the Other sector.
When did Central Asia Lumeichun Biotechnology complete a stock split?▼
The last stock split for Central Asia Lumeichun Biotechnology was on July 28, 2026 with a ratio of 1:500.
Where is Central Asia Lumeichun Biotechnology headquartered?▼
Central Asia Lumeichun Biotechnology is headquartered in Winter Park, United States.